Premium
EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN
Author(s) -
Choquet S.,
PérezSimón J. A.,
Worel N.,
Chaganti S.,
Dinavahi R.,
GuzmanBecerra N.,
Navarro W.,
Sun Y.,
Gamelin L.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.170_2880
Subject(s) - ibrutinib , medicine , oncology , cd8 , immune system , pharmacology , immunology , leukemia , chronic lymphocytic leukemia